Subtype
Large Intestinal Neoplasm
CI-CAN-00001062Explore in graph →
Non-malignant1,849 active trials21 approved drugs383 evidence items
- NCIt
- C215201
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001062Explore in graph →
Clinical trials
8,851 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03008499 | High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer | completed | Phase 1 / Phase 2 | 20 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT03357276 | Mix Vaccine for Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 30 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT00501410 |
| FOLFOX Chemotherapy Regimen (5-FU, Leucovorin, Oxaliplatin) in Metastatic Colorectal Cancer |
| completed |
| Phase 1 |
| 86 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Aug 28, 2019 |
| clinicaltrials |
| NCT00656123 | Study of Colon GVAX and Cyclophosphamide in Patients With Metastatic Colorectal Cancer | completed | Phase 1 | 9 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 14, 2019 | clinicaltrials |
| NCT02876224 | Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors | completed | Phase 1 | 51 | Hoffmann-La RocheINDUSTRY | 2 | Aug 13, 2019 | clinicaltrials |
| NCT03204201 | Validation of ICG to Identify the Urethra During Rectal Surgery | terminated | Phase 1 / Phase 2 | 5 | Oxford University Hospitals NHS TrustOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03204994 | Fluorescence Targeted Pelvic Lymph Node Mapping | terminated | Phase 1 / Phase 2 | 1 | Oxford University Hospitals NHS TrustOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT02613221 | A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer(APOLLON) | completed | Phase 1 / Phase 2 | 56 | TakedaINDUSTRY | 1 | Jul 31, 2019 | clinicaltrials |
| NCT04035096 | The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients | unknown | Phase 1 / Phase 2 | 40 | National Taiwan University HospitalOTHER | 1 | Jul 29, 2019 | clinicaltrials |
| NCT03677960 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | terminated | Phase 1 | 6 | Antiva BiosciencesINDUSTRY | 2 | Jul 24, 2019 | clinicaltrials |
| NCT02069704 | Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients | completed | Phase 1 | 142 | mAbxience Research S.L.INDUSTRY | 5 | Jul 23, 2019 | clinicaltrials |
| NCT02952989 | A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors | terminated | Phase 1 | 47 | Seagen Inc.INDUSTRY | 1 | Jul 19, 2019 | clinicaltrials |
| NCT01890213 | Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer | completed | Phase 1 | 12 | Duke UniversityOTHER | 1 | Jul 18, 2019 | clinicaltrials |
| NCT02973672 | Phase I of SGM-101 in Patients With Cancer of the Colon, Rectum or Pancreas | completed | Phase 1 / Phase 2 | 75 | SurgimabINDUSTRY | 1 | Jul 18, 2019 | clinicaltrials |
| NCT03694080 | Calcium Electroporation for Early Colorectal Cancer | unknown | Phase 1 | 24 | Zealand University HospitalOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT04008511 | Regorafenib and XELOX as 2nd Line Treatment in Metastatic Colorectal Cancer | unknown | Phase 1 / Phase 2 | 54 | China Medical University, ChinaOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT00004187 | Capecitabine and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | — | Swiss Cancer InstituteOTHER | 1 | Jun 26, 2019 | clinicaltrials |
| NCT03993626 | A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer(CAROSELL) | unknown | Phase 1 / Phase 2 | 55 | Celleron Therapeutics Ltd.INDUSTRY | 1 | Jun 21, 2019 | clinicaltrials |
| NCT03431311 | T Cell Receptor Based Therapy of Metastatic Colorectal Cancer(TCR-CRC-001) | terminated | Phase 1 / Phase 2 | 1 | Oslo University HospitalOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT02266355 | Role of Omalizumab in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction | completed | Phase 1 | 9 | Yale UniversityOTHER | 1 | May 30, 2019 | clinicaltrials |
| NCT00869570 | External-Beam Radiation Therapy, Capecitabine, and Sorafenib in Treating Patients With Locally Advanced Rectal Cancer | completed | Phase 1 / Phase 2 | 54 | Swiss Cancer InstituteOTHER | 2 | May 15, 2019 | clinicaltrials |
| NCT01985763 | Genistein in Treatment of Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 13 | Sofya PintovaOTHER | 1 | May 10, 2019 | clinicaltrials |
| NCT01183494 | A Genotype-guided Study of Irinotecan Administered in Combination With 5-fluorouracil/Leucovorin (FOLFIRI) and Bevacizumab in Advanced Colorectal Cancer Patients | completed | Phase 1 | 17 | University of ChicagoOTHER | 2 | Apr 22, 2019 | clinicaltrials |
| NCT01206530 | FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer | completed | Phase 1 / Phase 2 | 50 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Apr 18, 2019 | clinicaltrials |
| NCT00088413 | PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Apr 16, 2019 | clinicaltrials |
| NCT00403052 | A Study of 1018 Immunostimulatory Sequence (ISS) Administered With Irinotecan and Cetuximab to Treat Patients With Previously Treated Metastatic Colorectal Cancer | terminated | Phase 1 | 14 | Dynavax Technologies CorporationINDUSTRY | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03904537 | A Study of Combination of Anti-PD1 Antibody-activated TILs and Chemotherapy in Colorectal Cancer | unknown | Phase 1 / Phase 2 | 20 | Sun Yat-sen UniversityOTHER | 1 | Apr 5, 2019 | clinicaltrials |
| NCT00645710 | Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery | completed | Phase 1 / Phase 2 | 16 | City of Hope Medical CenterOTHER | 1 | Mar 28, 2019 | clinicaltrials |
| NCT02568046 | Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients | terminated | Phase 1 / Phase 2 | 10 | Symphogen A/SINDUSTRY | 2 | Mar 26, 2019 | clinicaltrials |
| NCT00409994 | Safety Study of Rapamycin Administered Before and During Radiotherapy to Treat Rectum Cancer | completed | Phase 1 / Phase 2 | 44 | Maastricht Radiation OncologyOTHER | 1 | Mar 18, 2019 | clinicaltrials |
| NCT02116894 | Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer(REGAL-1) | completed | Phase 1 | 11 | Duke UniversityOTHER | 1 | Mar 14, 2019 | clinicaltrials |
| NCT02745769 | A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents | completed | Phase 1 | 23 | Eli Lilly and CompanyINDUSTRY | 3 | Mar 5, 2019 | clinicaltrials |
| NCT02298946 | AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer | completed | Phase 1 | 17 | National Cancer Institute (NCI)NIH | 1 | Feb 22, 2019 | clinicaltrials |
| NCT00844064 | Safety and Tolerability of AP 12009, Administered I.V. in Patients With Advanced Tumors Known to Overproduce TGF-beta-2 | completed | Phase 1 | 62 | Isarna Therapeutics GmbHINDUSTRY | 1 | Feb 15, 2019 | clinicaltrials |
| NCT02991196 | Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer | terminated | Phase 1 | 4 | Daiichi SankyoINDUSTRY | 1 | Feb 12, 2019 | clinicaltrials |
| NCT01871311 | A Phase I Study of Nilontinib and Cetuximab in Patients With Solid Tumors | terminated | Phase 1 | 15 | Georgetown UniversityOTHER | 1 | Feb 8, 2019 | clinicaltrials |
| NCT03202992 | Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection | completed | Phase 1 | 57 | Antiva BiosciencesINDUSTRY | 2 | Feb 7, 2019 | clinicaltrials |
| NCT02433626 | Study of COTI-2 as Monotherapy or Combination Therapy for the Treatment of Malignancies(COTI2-101) | unknown | Phase 1 | 51 | Critical Outcome Technologies Inc.INDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT02648386 | Stem Cell Therapy Combined With NeuroRegen Scaffold™ in Patients With Erectile Dysfunction After Rectal Cancer Surgery | unknown | Phase 1 / Phase 2 | 34 | Chinese Academy of SciencesOTHER_GOV | 1 | Jan 25, 2019 | clinicaltrials |
| NCT02205398 | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | terminated | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 7 | Jan 22, 2019 | clinicaltrials |
| NCT02726334 | A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer. | terminated | Phase 1 | 22 | Bionomics LimitedINDUSTRY | 1 | Jan 16, 2019 | clinicaltrials |
| NCT03634501 | Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer（NK）Cells | unknown | Phase 1 / Phase 2 | 200 | Xuanwu Hospital, BeijingOTHER | 1 | Jan 11, 2019 | clinicaltrials |
| NCT01923337 | Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer | completed | Phase 1 | 17 | University of California, DavisOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02655952 | Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients | completed | Phase 1 | 17 | WntResearch ABINDUSTRY | 2 | Dec 28, 2018 | clinicaltrials |
| NCT02860780 | A Study of Prexasertib (LY2606368) in Combination With Ralimetinib in Participants With Advanced or Metastatic Cancer | completed | Phase 1 | 9 | Eli Lilly and CompanyINDUSTRY | 2 | Dec 14, 2018 | clinicaltrials |
| NCT01282502 | Midostaurin (PKC412) for Locally Advanced Rectal Cancer | completed | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Dec 12, 2018 | clinicaltrials |
| NCT01560377 | Perfusion Assessment in Laparoscopic Left Anterior Resection(PILLAR II) | completed | Phase 1 | 147 | Novadaq Technologies ULC, now a part of StrykerINDUSTRY | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00923520 | A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2018 | clinicaltrials |
| NCT02960594 | hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse(TRT-001) | completed | Phase 1 | 93 | Inovio PharmaceuticalsINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT02391727 | Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors(SYN004_Ph_1) | completed | Phase 1 | 10 | Synermore Biologics Co., Ltd.INDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Sep 12, 2019source: clinicaltrials